Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition for treating pneumoconiosis

A composition and drug technology, applied in the direction of drug combination, medical formula, plant raw material, etc., can solve the problems of unsatisfactory treatment effect, unsuitable for large-scale use, cumbersome use method, etc., so as to improve body immunity, enhance Pulmonary ventilation function and the effect of reducing toxic and side effects

Inactive Publication Date: 2015-10-07
JINAN ZHENGQI BIOTECHNOLOGY CO LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the past, the treatment of pneumoconiosis mostly used a single species, such as zinc gluconate, quinoquinone phosphate, tirole hydrochloride, yellow root and other drugs. These drugs are not effective when used alone, and the overall therapeutic effect is not satisfactory; Some pure Chinese medicine prescriptions for the treatment of pneumoconiosis, some are palliative, not the root cause, some use expensive ingredients, some are discontinued due to inaccurate curative effect during the application process, and some are more cumbersome and not suitable for wide-scale use
In short, there has been a lack of an effective combined prescription for the treatment of pneumoconiosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] A medicine for treating pneumoconiosis. The components are calculated in parts by weight, and the ratio is as follows: 15 parts of Platycodon grandiflorum, 2 parts of tirole hydrochloride, 10 parts of astragalus, 5 parts of licorice, and 15 parts of Bupleurum.

[0031] The raw materials and medicines of the above components are mixed evenly, and they are jointly pulverized into a coarse powder, which is passed through a 50-100 mesh sieve, and the sieved crude drug powder is made into tablets, and every 30 tablets are packed in a bottle as a finished product.

[0032] In the above prescription, each serving is 1g.

Embodiment 2

[0034] A medicine for treating pneumoconiosis. The components are calculated in parts by weight, and the proportion is as follows: 10 parts of bellflower, 3 parts of tirole hydrochloride, 5 parts of astragalus, 8 parts of licorice, and 10 parts of bupleurum.

[0035] The raw materials and medicines of the above components are mixed evenly, and they are jointly pulverized into a coarse powder, which is passed through a 50-100 mesh sieve, and the sieved crude drug powder is made into tablets, and every 30 tablets are packed in a bottle as a finished product.

[0036] In the above prescription, each serving is 5g.

Embodiment 3

[0038] A medicine for treating pneumoconiosis. The components are calculated in parts by weight, and the proportion is as follows: 20 parts of platycodon grandiflorum, 2 parts of tirole hydrochloride, 10 parts of astragalus, 5 parts of licorice and 20 parts of Bupleurum.

[0039] The raw materials and medicines of the above components are mixed evenly, and they are jointly pulverized into a coarse powder, which is passed through a 50-100 mesh sieve, and the sieved crude drug powder is made into tablets, and every 30 tablets are packed in a bottle as a finished product.

[0040] In the above prescription, each serving is 5g.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a drug, in particular to pharmaceutical composition for treating pneumoconiosis. The pharmaceutical composition comprises, by weight, 10-20 parts of radix platycodi, 1-3 parts of tilorone oxime hydrochloride, 5-10 parts of astragalus, 3-9 parts of radix glycyrrhizae and 10-20 parts of radix burpleuri. According to the pharmaceutical composition for treating the pneumoconiosis, due to the fact that part of western medicine and part of traditional Chinese medicine are adopted, the price is low, and the pharmaceutical composition for treating the pneumoconiosis can be used and popularized in a wide range; due to the fact that pure natural traditional Chinese medicine such as the astragalus and the radix glycyrrhizae is adopted, side effects of the medicine are reduced; tablet packing is adopted, a patient can take the medicine everyday conveniently and can carry the medicine conveniently for use at any time, pain of the patient during an attack is relieved, and the pharmaceutical composition for treating the pneumoconiosis is suitable for pneumoconiosis patients of all ages and at various stages; the course of treatment is short, and the effect is fast.

Description

technical field [0001] The invention relates to a medicine, in particular to a medicine composition for treating pneumoconiosis. Background technique [0002] Pneumoconiosis refers to a lung disease characterized by fibrous tissue hyperplasia caused by long-term inhalation of large amounts of respirable dust by workers during occupational activities. The basic lesions of pneumoconiosis are the formation of silicon nodules and extensive fibrosis of the pulmonary interstitium. The formation of silicon nodules due to lung tissue fibrosis is irreversible. If you get this disease, it will gradually develop and eventually lead to death due to the loss of respiratory function of the lungs. [0003] According to the figures released by the Ministry of Health, since the 1950s, as of 2005, a total of 607,570 cases of pneumoconiosis have been reported in my country, which is equivalent to the sum of pneumoconiosis patients in other countries in the world, and more than 140,000 people h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/484A61P11/00
Inventor 杨茜
Owner JINAN ZHENGQI BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com